TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results

GlobeNewswire Inc. Logo GlobeNewswire Inc. By 60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results

60 Degrees Pharmaceuticals reported Q3 2025 financial results with 223% net product revenue increase, but experienced a gross loss due to inventory write-off. The company is exploring new treatment indications for tafenoquine, including potential treatments for canine babesiosis and chronic babesiosis.

Insights
ARKQ   positive

Actively managed with unique AI and robotics investments, focuses beyond mega-cap stocks, reasonable 0.75% expense ratio


SXTP   neutral

Mixed financial performance with revenue growth but increased losses, ongoing research and development efforts, and strategic partnerships indicate potential future opportunities